Fig. 5

Detection of KLF12 and FOXO1 expression in patients with RIF. The KLF12 (a) and FOXO1 (b) transcript levels in the uteri of fertile (n = 11) and RIF (n = 12) patients were quantified by real-time PCR and were then normalized to control 18S gene expression. The data are presented with respect to the fertile group (expression was set to 1). *P < 0.05 and ***P < 0.001 compared with the fertile group. FER, normal fertility women. c The difference in protein expression in endometrial samples was assessed by Western blotting using antibodies specific to KLF12 and FOXO1. Total KLF12 (d) and FOXO1 (e) protein levels were normalized to GAPDH expression, and the data for all of the endometrial samples are shown in the scatter plots. f Correlation between KLF12 and FOXO1 protein expression (n = 23, P < 0.05). g Immunohistochemical analysis using KLF12 and FOXO1 antibodies. Endometrial tissue samples from fertile women and those with RIF are shown at 200× (left panel) and 400× (right panel) magnification. The negative control (NC) is nonspecific rabbit serum, and the positive controls are mouse kidney tissue (KLF12) and human breast carcinoma tissue (FOXO1), respectively. Brown represents positive staining (arrows). Scale bar, 100 μm (left panel) and 50 μm (right panel)